Novo Nordisk Annual Report 2021

Contents Introducing Novo Nordisk Strategic Aspirations Key risks Management Consolidated statements Additional information Novo Nordisk Annual Report 2021 6 Novo Nordisk at a glance Novo Nordisk is a global healthcare company, headquartered in Denmark. Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world. We aim to lead in all disease areas in which we are active. Our corporate strategy Our corporate strategy has four distinct focus areas in which we operate. It is built on our purpose, the Novo Nordisk Way and our ambition to be a sustainable business. We aim to strengthen our leadership and treatment options in Diabetes and Obesity care, secure leading positions within Biopharm and establish a strong presence in other serious chronic diseases such as NASH, cardiovascular disease and Alzheimer's disease. Succeeding in this will drive sustainable growth for Novo Nordisk. 140,800 DKK million in net sales 168 countries with marketed products 58,644 DKK million in operating profit 80 countries with affiliates Diabetes care Strengthen leadership by offering innovative medicines and driving patient outcomes Novo Nordisk 29,319 DKK million in free cash flow 5 countries with R&D facilities 48,478 employees worldwide Biopharm Secure a leading position by leveraging full portfolio and expanding into adjacent areas Way Driving change to defeat diabetes and other serious chronic diseases Sustainable business DG Obesity care Strengthen treatment options through market development and by offering innovative medicines and driving patient outcomes Other serious chronic diseases Establish presence by building competitive pipeline and scientific leadership

View entire presentation